Skip Navigation


BJA Advance Access originally published online on October 20, 2009
British Journal of Anaesthesia 2009 103(6):858-860; doi:10.1093/bja/aep293
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
103/6/858    most recent
aep293v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Liu, N.
Right arrow Articles by Fischler, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, N.
Right arrow Articles by Fischler, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author [2009]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournal.org

Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma

N. Liu1, S. Aldea2, D. François3, M. Cherqui-Michel1, M. Giansily-Blaizot4 and M. Fischler1,*

1 Department of Anaesthesiology,
2 Department of Neurosurgery and
3 Department of Biology, Hôpital Foch, 40 rue Worth, 92151 Suresnes, France
4 Department of Hemostasis, CHU Montpellier, France

* Corresponding author. E-mail: m.fischler{at}hopital-foch.org

Inherited factor VII (FVII) deficiency is a rare autosomal-recessive bleeding disorder. There are no clear guidelines regarding therapy in such patients when intracerebral surgery is performed. We report the use of recombinant activated FVII (rFVIIa) for the prophylaxis of bleeding in a female with FVII deficiency (8% of activity) undergoing urgent removal of a right fronto-rolandic intracerebral haematoma secondary to a bleeding from a cavernous angioma. To assist haemostasis during and after surgery, rFVIIa boluses were administered during the procedure and continued every 12 h during 3 days after operation to maintain a prothrombin time <15 s. Using this approach, no abnormal bleeding or thromboembolic complications were observed and rFVIIa appeared safe in this context.

Keywords: blood, coagulation; complications, factor VII deficiency; neurosurgery, hemangioma, cavernous; recombinant FVIIa


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.